131 related articles for article (PubMed ID: 21235585)
1. Mechanism of cytochrome P450-3A inhibition by ketoconazole.
Greenblatt DJ; Zhao Y; Venkatakrishnan K; Duan SX; Harmatz JS; Parent SJ; Court MH; von Moltke LL
J Pharm Pharmacol; 2011 Feb; 63(2):214-21. PubMed ID: 21235585
[TBL] [Abstract][Full Text] [Related]
2. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
Patki KC; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2003 Jul; 31(7):938-44. PubMed ID: 12814972
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
4. Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.
Greenblatt DJ; Venkatakrishnan K; Harmatz JS; Parent SJ; von Moltke LL
Xenobiotica; 2010 Oct; 40(10):713-20. PubMed ID: 20712450
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450-dependent metabolism of midazolam in hepatic microsomes from chickens, turkeys, pheasant and bobwhite quail.
Cortright KA; Craigmill AL
J Vet Pharmacol Ther; 2006 Dec; 29(6):469-76. PubMed ID: 17083450
[TBL] [Abstract][Full Text] [Related]
6. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
Chen M; Nafziger AN; Bertino JS
Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
[TBL] [Abstract][Full Text] [Related]
7. Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes.
Patki KC; Greenblatt DJ; von Moltke LL
J Pharm Pharmacol; 2004 Aug; 56(8):963-6. PubMed ID: 15285839
[TBL] [Abstract][Full Text] [Related]
8. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
[TBL] [Abstract][Full Text] [Related]
9. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD
Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530
[TBL] [Abstract][Full Text] [Related]
10. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
[TBL] [Abstract][Full Text] [Related]
11. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Martínez C; García-Martín E; Pizarro RM; García-Gamito FJ; Agúndez JA
Br J Cancer; 2002 Sep; 87(6):681-6. PubMed ID: 12237780
[TBL] [Abstract][Full Text] [Related]
12. Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole.
Zhuang X; Zhang T; Yue S; Wang J; Luo H; Zhang Y; Li Z; Che J; Yang H; Li H; Zhu M; Lu C
Biochem Pharmacol; 2016 Dec; 121():67-77. PubMed ID: 27666601
[TBL] [Abstract][Full Text] [Related]
13. [Effect of ketoconazole on the activity of CYP4503A4 and CYP450 1A2 of hepatic microsomes in healthy adults].
Yang GZ; Yuan Y; Zhou QX; Yang JQ; Liu YJ
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1634-5, 1639. PubMed ID: 18819885
[TBL] [Abstract][Full Text] [Related]
14. The combination of chemical and antibody inhibitors for superior P450 3A inhibition in reaction phenotyping studies.
Rock DA; Foti RS; Pearson JT
Drug Metab Dispos; 2008 Dec; 36(12):2410-3. PubMed ID: 18765682
[TBL] [Abstract][Full Text] [Related]
15. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes.
Zhang S; Pillai VC; Mada SR; Strom S; Venkataramanan R
Xenobiotica; 2012 May; 42(5):409-16. PubMed ID: 22106961
[TBL] [Abstract][Full Text] [Related]
16. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
[TBL] [Abstract][Full Text] [Related]
17. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
18. Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and Small-Intestine Tissues Efficiently Metabolizes Midazolam, Alprazolam, Nifedipine, and Testosterone.
Uehara S; Uno Y; Nakanishi K; Ishii S; Inoue T; Sasaki E; Yamazaki H
Drug Metab Dispos; 2017 May; 45(5):457-467. PubMed ID: 28196829
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys.
Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
Drug Metab Dispos; 2010 Nov; 38(11):1967-75. PubMed ID: 20702772
[TBL] [Abstract][Full Text] [Related]
20. Investigation of drug-drug interaction via mechanism-based inhibition of cytochrome P450 3A by macrolides in dexamethasone-treated female rats.
Kanazu T; Sato N; Kadono K; Touchi A; Takeda Y; Yamaguchi Y; Baba T
Biopharm Drug Dispos; 2012 May; 33(4):195-206. PubMed ID: 22447511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
